These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8522818)

  • 41. DTCA not real advertising issue.
    Saunders B
    N Z Med J; 2003 Sep; 116(1182):U611. PubMed ID: 14581960
    [No Abstract]   [Full Text] [Related]  

  • 42. [Political measures have a long-term effect on the drug industry].
    Engelhorn C
    Fortschr Med; 1980 Apr; 98(14):501-2, 544. PubMed ID: 7372245
    [No Abstract]   [Full Text] [Related]  

  • 43. [Parallel import of drugs for better and for worse].
    Krabbe U
    Ugeskr Laeger; 2004 Feb; 166(7):611. PubMed ID: 15005051
    [No Abstract]   [Full Text] [Related]  

  • 44. IP litigation in China could drive innovation.
    Jia H
    Nat Biotechnol; 2004 Apr; 22(4):368. PubMed ID: 15060539
    [No Abstract]   [Full Text] [Related]  

  • 45. More drugs, less protection.
    Nature; 2002 Sep; 419(6904):233. PubMed ID: 12239521
    [No Abstract]   [Full Text] [Related]  

  • 46. Biotech drug market steadily expands.
    Lawrence S
    Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
    [No Abstract]   [Full Text] [Related]  

  • 47. API Global Sourcing Strategies 2010.
    Bennett S
    IDrugs; 2010 Sep; 13(9):605-6. PubMed ID: 20799139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. No cure, no pay.
    Møldrup C
    BMJ; 2005 May; 330(7502):1262-4. PubMed ID: 15920131
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmaceuticals issue brief: pharmaceutical assistance programs: year end report--2004.
    Seay M
    Issue Brief Health Policy Track Serv; 2004 Dec; ():1-26. PubMed ID: 15724309
    [No Abstract]   [Full Text] [Related]  

  • 50. Direct-to-consumer advertising is more profitable if it is misleading.
    Mansfield PR; Mintzes B
    N Z Med J; 2003 Sep; 116(1182):U610. PubMed ID: 14581959
    [No Abstract]   [Full Text] [Related]  

  • 51. Pharmaceutical and other commercial uses of the dog model.
    Ikeda-Douglas CJ; de Rivera C; Milgram NW
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):355-60. PubMed ID: 15795043
    [No Abstract]   [Full Text] [Related]  

  • 52. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
    Ghosh S
    Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
    [No Abstract]   [Full Text] [Related]  

  • 53. Billion dollar babies--biotech drugs as blockbusters.
    Lawrence S
    Nat Biotechnol; 2007 Apr; 25(4):380-2. PubMed ID: 17420735
    [No Abstract]   [Full Text] [Related]  

  • 54. [Responsibility for drug testing and control].
    Büchi J
    Pharm Acta Helv; 1968 Sep; 43(9):619-27. PubMed ID: 5718866
    [No Abstract]   [Full Text] [Related]  

  • 55. Can complexity be commercialized?
    Mack GS
    Nat Biotechnol; 2004 Oct; 22(10):1223-9. PubMed ID: 15470456
    [No Abstract]   [Full Text] [Related]  

  • 56. Quality control of pharmaceutical preparations and the Third World.
    Summers RS
    Cent Afr J Med; 1983 Dec; 29(12):247-9. PubMed ID: 6671214
    [No Abstract]   [Full Text] [Related]  

  • 57. More than meets the eyes?
    Jacobs T
    Nat Biotechnol; 2004 Oct; 22(10):1221. PubMed ID: 15470455
    [No Abstract]   [Full Text] [Related]  

  • 58. Trading on traditional medicines.
    Basu P
    Nat Biotechnol; 2004 Mar; 22(3):263-5. PubMed ID: 14990941
    [No Abstract]   [Full Text] [Related]  

  • 59. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 60. Triage in the nation's medicine cabinet: the puzzling scarcity of vaccines and other drugs.
    Noah L
    S C Law Rev; 2002; 54(2):371-403. PubMed ID: 15156891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.